Immunovaccine Inc. (TSX-V: IMV) is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health.
The company has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. Immunovaccine is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax, as well as an anti-cocaine vaccine program in collaboration with Weill Cornell Medical College. In addition to the company's human health vaccine strategym it continues to capture value from animal health vaccine applications, including an ongoing collaboration with Pfizer Animal Health.
Corporate Presentation:
Paradigm Capital Inc.
Senior Analyst: Alan Ridgeway
Tel: 416.361.9080
Paradigm Capital initated coverage Feb. 26, 2010
Zacks Investment Research
Senior Biotech Analyst: Grant Zeng, CFA
Tel: 312-265-9466
Zacks initated coverage August 21, 2012
